Context: Leptin alters bone and mineral metabolism in rodents, but this has not been verified in humans. Patients with congenital generalized lipodystrophy (CGL) have low leptin due to deficient adipose mass and serve as models of leptin deficiency and replacement.
Although several controversies remain unresolved, many of which have been reviewed in recent literature (11) , leptin has generally been shown to impact bone metabolism via two distinct mechanisms: leptin directly increases bone mass through stimulation of osteoblast differentiation and proliferation, and it indirectly decreases bone mass through ␤-adrenergic receptor-mediated sympathetic nervous system activity. Increasing the complexity of the apparent role of leptin in bone metabolism is recent work demonstrating the interplay of leptin and the PTH/fibroblast growth factor 23 (FGF23) axis (12) . Regardless of the molecular mechanisms, leptin deficiency results in a specific bone phenotype in rodents, consisting of increased trabecular bone and decreased cortical bone in the vertebrae (13, 14) and decreased cortical bone in the limbs (14, 15) . This phenotype was initially described in leptin-deficient ob/ob mice, but the same phenotype (increased vertebral trabecular bone) has been observed in two additional models of inadequate leptin signaling: leptin-resistant db/db, and lipoatrophic leptin-deficient A-ZIP mice (13) . Because the appendicular skeleton comprises about 80% of bone mass and is primarily cortical bone, the net result of leptin deficiency on the mouse skeleton is a decrease in total-body bone mass. Leptin gene therapy in ob/ob mice increased cortical bone in the femur and decreased trabecular bone in the vertebrae, essentially reversing the bone phenotype (15) and increasing totalbody bone mineral content (BMC) (16) .
Understanding the role of leptin in human bone health requires selection of an appropriate disease model. Leptin deficiency in humans has been described in several disease states. Congenital leptin deficiency, caused by a mutation in the leptin gene, is an exceedingly rare condition that leads to severe obesity and hyperphagia beginning in early childhood, as well as hypogonadotropic hypogonadism (17) ; the resultant sex-steroid deficiency can lower bone mass independent of the effects of leptin. Congenital generalized lipodystrophy (CGL), in which there is severe deficiency of adipose tissue (and hence, adipokines such as leptin), represents an excellent model for understanding the actions of leptin on bone in a state of deficiency and replacement. Unlike patients with congenital leptin deficiency, patients with CGL are nonobese, but they have more extreme manifestations of the metabolic syndrome due to ectopic lipid storage (18, 19) . Leptin replacement in CGL reduces food intake (20, 21) and ameliorates most metabolic abnormalities, including insulin resistance (21) (22) (23) , diabetes (22, 24, 25) , hypertriglyceridemia (23) (24) (25) , and hepatic steatosis (21, 26) . CGL, as compared with congenital leptin deficiency, exhibits a slightly less severe hypoleptinemia (albeit still a profound deficiency), which allows for relatively normal pubertal development and sex steroid production. These factors, in addition to its relatively greater prevalence, make CGL an interesting model in which to study the effects of leptin on bone and mineral metabolism in humans.
In this analysis, we examined BMC by dual-energy x-ray absorptiometry (DXA) and mineral metabolism in 31 patients with CGL before and after receiving leptin replacement therapy. We hypothesized that in the leptin-deficient state, CGL patients would have decreased total-body BMC, which would normalize with leptin replacement.
Patients and Methods

Patients
The present study was an ancillary study of a protocol at the Clinical Center of the National Institutes of Health (NIH) designed to study the effects of recombinant human methionyl leptin (metreleptin; Bristol Myers Squibb) replacement on metabolic and hormonal derangements in patients with lipodystrophy (NCT00025883). The study was approved by the Institutional Review Board of the National Institute of Diabetes and Digestive and Kidney Diseases. All patients or their parents provided informed consent, and minors (age, Ͻ18 y) gave assent. Patients met the following requirements for study eligibility: a clinical diagnosis of lipodystrophy; a fasting leptin level Ͻ 12 ng/mL in females or Ͻ 8 ng/mL in males; and at least one metabolic complication of lipodystrophy (diabetes as defined by 2007 American Diabetes Association criteria, fasting insulin Ͼ 217 pmol/L, or fasting triglycerides Ͼ 2.25 mmol/L). Patients were ineligible for the study if they had known infectious liver disease or alcohol abuse, known HIV infection, psychiatric disorders, or other diseases impeding competence or compliance, or used anorexigenic drugs. All patients received self-administered sc metreleptin, 0.06 -0.24 mg/kg/d in one or two divided doses, with doses adjusted to optimize metabolic control of triglycerides and hemoglobin A1C while minimizing excessive weight loss.
BMC and bone metabolism parameters were assessed before initiation of metreleptin and 6 months to 11 years later. Thirtyfour patients enrolled in the main trial with a diagnosis of CGL had at least one DXA scan performed. Three patients were excluded from analyses due to severe comorbidities that could alter bone accrual, growth, and/or mineral metabolism independently of leptin (hepatopulmonary syndrome with severe hypoxemia, advanced cirrhosis with hepatic encephalopathy, and kidney transplantation). Sensitivity analyses including these three patients did not show any substantive difference in results from the data presented here for the remaining 31 patients.
Evaluation of BMC
BMC was measured using DXA (Hologic QDR 4500; Hologic Inc). Whole-body DXA scans were analyzed and reviewed by a single radiologist at the National Institutes of Health Clinical Research Center (J.C.R.). Long-term instrument precision as measured by daily spine phantom scans had a coefficient of variation of less than 0.4%. BMC was used rather than bone mineral density (BMD) because of the variability of bone area calculation attributable to irregularities in bone shape when assessing totalbody scans. Preliminary assessments demonstrated no major dif-ferences in results when BMD measurements were used. Because of the distinct physiology of the skull and the changing contribution of the skull relative to the remainder of the skeleton in growing children, BMC of the total body less the head (TBLH) was used.
Because BMC changes with growth and development, SD scores (SDS) for BMC were calculated based on normative population data from the Bone Mineral Density in Childhood Study (BMDCS) (27) . For patients under the age of 20 years at the time of the DXA, SDS represent Z-scores (compared to age-matched controls). For patients over the age of 20 years, SDS represent Tscores (compared to 20-y-old controls). TBLH BMC SDS were determined using an online calculator (http://www.bmdcspublic. com/zscore.htm) and data from the BMDCS (Clinical Trials and Surveys Corp). Sex-, race-(African American vs non-African American), and age-matched children and adults comprised the reference population (27) . For height-adjusted values, sex-, race-, age-, and height-matched controls were used.
In eight patients, site-specific DXA scans were obtained for the anteroposterior (AP) spine, total hip, and 1/3 radius. Heightadjusted SDS for BMD at these sites was calculated using the BMDCS online calculator, as above. Because few patients had site-specific data available, estimates of cortical vs trabecular bone were obtained from whole-body DXA as follows. The axial skeleton (spine, ribs, and pelvis) was assumed to be comprised primarily of trabecular bone; the appendicular skeleton (arms and legs), primarily cortical bone. Because normative data for axial and appendicular BMC are not available in growing children, the ratio of appendicular to axial BMC, which should remain relatively constant during childhood growth and development after age 5, was calculated to partially normalize for effects of growth.
Evaluation of body composition
Lean body mass and fat mass were measured using DXA as described above. Because lean body mass also changes with growth and development, SDS for lean mass index (LMI), defined as lean body mass per height-squared, was calculated using population normative data from the National Health and Nutrition Examination Survey as previously described (28) .
Assessment of growth and development
Height was measured using a wall-mounted stadiometer. In patients who had completed growth at the time of study entry, the initial height measurement was carried forward for all subsequent time points. Weight was measured in the morning at each visit. Body mass index (BMI) was calculated as body weight (kilograms) divided by height (meters) squared. Bone age was assessed by a single pediatric endocrinologist (R.J.B.) using the Greulich and Pyle method (29) . Bone age advancement was determined by subtracting chronological age from bone age. Pubertal staging was assessed by breast development in girls and testicular volume in boys.
Laboratory measures
Blood samples were obtained after an overnight fast. Leptin was measured by RIA using a commercial kit (Linco Research). Osteocalcin was measured by enhanced chemiluminescence. 25-Hydroxyvitamin D was assayed by liquid chromatography/mass spectroscopy. 1,25-Dihydroxyvitamin D was measured via RIA at Mayo Medical Laboratories. IGF-1, GH, T, estradiol, hemoglobin A1C, and triglycerides were measured in the NIH Clinical Center laboratory according to standard methodology. Total serum calcium was corrected for albumin according to the following equation:
Statistics
Results are presented as mean Ϯ SD, unless indicated otherwise. Statistical analyses were performed using GraphPad Prism version 6.01 for Windows (GraphPad Software Inc) and SAS Enterprise Guide 5.1 (SAS Institute Inc). Paired t tests were used to compare data that were normally distributed; for nonparametric data, Wilcoxon matched-pairs tests were used. For repeated-measures analysis, mixed models (PROC MIXED) were used. A P value Ͻ .05 was considered statistically significant. Age was included as a covariate in mixed models testing outcomes that are known to change with age and for which age-specific population normative data were not available to calculate SDS (including phosphorus and fat mass). For parameters assessed at baseline, associations were determined via linear regression, and a significantly nonzero slope (P Ͻ .05) was considered to demonstrate statistical significance. Because the study continuously enrolled patients over a 13 years period, the duration of follow-up was variable, and not all parameters were available for each patient at each visit. Therefore, for each set of results given here, the duration of metreleptin treatment was grouped into 6-month intervals, and the number of patient measurements included in each analysis is presented.
Results
Baseline characteristics
The baseline characteristics of all 31 patients are given in Table 1 . All patients had low fat mass and very low endogenous leptin levels: mean fasting leptin was 1.3 Ϯ 0.9 ng/dL in females and 0.7 Ϯ 0.4 ng/dL in males. Six patients were 18 years of age or older at baseline; 20 patients were 10 to 17 years of age; and five patients were Ͻ 10 years of age.
Before metreleptin treatment, patients with CGL had significantly increased TBLH BMC SDS (1.8 Ϯ 0.7; n ϭ 29; P Ͻ .0001), LMI SDS (1.5 Ϯ 0.8; n ϭ 29; P Ͻ .001), and height SDS (1.3 Ϯ 1.3; n ϭ 31; P Ͻ .0001), compared to the general population ( Figure 1 ). There was no association between height SDS and TBLH BMC SDS (P ϭ .75). There was no difference between the BMC SDS of pediatric patients (defined as those patients under age 18) and those 18 years of age or older (P ϭ .90).
Before metreleptin treatment, no significant association was found between TBLH BMC SDS and 25-hydroxyvitamin D, 1,25-dihydroxy-vitamin D, IGF-1, GH, insulin, osteocalcin, free or total T, estradiol, or leptin level. The association between LMI and TBLH BMC SDS approached significance (P ϭ .06).
Nine of the pediatric patients in the cohort had bone age assessment at baseline; the average bone age advancement at baseline was 1.9 Ϯ 1.5 years. There was no association between bone age advancement and age at baseline (P ϭ .08) or BMC SDS (P ϭ .09).
Site-specific BMD data existed at baseline for only eight patients, and not every site was measured for each patient. BMD SDS were significantly greater than zero in the AP spine (2.1 Ϯ 1.5; P ϭ .01; n ϭ 7) and total hip (2.0 Ϯ 0.9; P ϭ .0004; n ϭ 8), but not in the 1/3 radius (0.8 Ϯ 1.8; P ϭ .26; n ϭ 8).
Effects of metreleptin
TBLH BMC SDS did not change (P ϭ .18) after metreleptin treatment (Figure 2) . At 12 months of treatment, there was no difference between the BMC SDS of pediatric patients and those over the age of 18 (P ϭ .48). BMI SDS decreased over time with metreleptin replacement (P Ͻ .0001) ( Figure 3A ). LMI SDS decreased from a mean of 1.5 Ϯ 0.83 at baseline to a mean of 0.58 Ϯ 0.54 at 96 months of treatment (P ϭ .0012) ( Figure 3B ), whereas fat mass did not change over time on metreleptin (P ϭ .12). Age, LMI SDS, and BMI SDS were not significant predictors of change in TBLH BMC SDS during metreleptin treatment. BMD SDS of the AP spine, total hip, and 1/3 radius did not change significantly from baseline with metreleptin replacement (P ϭ .19, P ϭ .40, and P ϭ .053, respectively) ( Figure 4 , A-C). In addition, the ratio of appendicular to axial BMC did not significantly change (P ϭ .76) after metreleptin ( Figure 4D ).
There was no significant change in PTH, phosphorus, osteocalcin, 25-hydroxyvitamin D, or 1,25-dihydroxyvitamin D with metreleptin. Mean albumin-corrected serum calcium at baseline was 2.38 mmol/L Ϯ 0.10, and it decreased significantly (P Ͻ .001) with metreleptin treatment, with a nadir mean calcium level of 2.23 Ϯ 0.05 at 120 months. Despite this decrease, there were no instances of biochemical or clinical hypocalcemia. 
Discussion
Our results demonstrate that patients with CGL before metreleptin treatment have elevated TBLH BMC compared to normative data for age, sex, race, and height. TBLH BMC did not change significantly with metreleptin treatment at doses sufficient to produce significant metabolic improvement (26) . The elevated trabecular bone observed in CGL at baseline is consistent with rodent models of leptin deficiency (13) . However, the findings for TBLH BMC in our population stand in contrast to data from rodent models, which demonstrated an overall decrease in total-body BMC with leptin deficiency and increased total-body BMC with leptin replacement (30) . Although much of the rodent literature on the role of leptin in bone biology is based on obese animal models (ob/ob and db/ db), the bone phenotype in the lipoatrophic A-ZIP mouse is consistent with that of the obese models (13) , supporting the role of leptin in this phenotype.
Why might CGL patients have high BMC in the leptindeficient state? As expected, compared to averaged-sized controls, individuals with tall stature have increased BMC measured by DXA due to larger bone size. However, even after accounting for height, TBLH BMC SDS remain high in CGL. Furthermore, there was no association between height SDS and height-adjusted TBLH BMC SDS, indicating that the BMDCS Z-score calculator appropriately adjusted for height in this population. Thus, the high observed TBLH BMC SDS in CGL appears to be independent of tall stature. However, it is conceivable that the increased BMC may also be due in part to a larger cross-sectional area for height, rather than increased bone density for height.
CGL patients also have high lean body mass, which is associated with increased BMC. The proposed mechanism for the association between increased lean mass and BMC is the exertion of greater force by muscle on bone, resulting in increased mineral content (31) . The effect of high lean mass on TBLH BMC SDS in our patients could not be directly assessed, because normative data for lean massadjusted TBLH BMC are only available from a small pediatric population with normal or low lean mass (32) , at the opposite extreme from CGL patients. The correlation between baseline TBLH BMC SDS and lean body mass in CGL approached significance, suggesting that high lean mass may have contributed to the high BMC in the leptin- deficient state. Lean body mass decreased with metreleptin; this might theoretically have decreased BMC, offsetting an increase in BMC directly resulting from metreleptin. However, changes in lean body mass during metreleptin treatment did not significantly predict changes in TBLH BMC SDS, suggesting that this is an unlikely explanation for the lack of change in BMC with metreleptin. A number of additional analyses were undertaken to explore potential explanations for the increased baseline BMC in CGL. Patients with CGL may have relatively early puberty, and adolescent and adult women may have hyperandrogenism from polycystic ovarian syndrome, both of which could contribute to increased sex steroid exposure and result in increased bone mass. Bone age advancement was examined as a marker of sex steroid exposure in our pediatric patients. Although bone ages were significantly advanced, the degree of bone age advancement at baseline was not significantly associated with the patient's age or with BMC SDS. Thus, sex steroid exposure, as assessed by bone age advancement, appears not to be associated with increased bone mass per se in our pediatric patient population. In addition, baseline BMC SDS was not significantly associated with serum T or estradiol in adults or children with CGL, suggesting that sex steroids were not major contributors to elevated BMC in this cohort. Additional commonly cited predictors of bone density-vitamin D, IGF-1, GH, as well as osteocalcin, a marker of bone formation-were not associated with baseline BMC in CGL, suggesting that they do not play a major role in the high bone mass phenotype. Other adipokines that were not here assessed may also partially explain the phenotype. In addition to leptin deficiency, CGL patients have very low adiponectin (33) ; however, the role of adiponectin in bone metabolism remains poorly understood, partly in view of apparently contradictory findings in vitro (34) and in vivo (35) in humans, and partly because the lack of pharmacologically available recombinant adiponectin renders replacement therapy impossible at present.
The lack of change in TBLH BMC SDS with metreleptin replacement, while in contrast to rodent data, supports earlier studies in humans. Our group previously investigated the effect of metreleptin replacement on whole-body BMC and BMD in 13 adults with lipodystrophy, including several with partial lipodystrophy, and found no changes with metreleptin replacement (20) . The effect of metreleptin on site-specific BMD was previously reported in two adult women with generalized lipodystrophy (37) . Both had normal BMD in the whole body, hip, spine, and radius before metreleptin treatment, and no significant changes were observed in any site after 16 -18 months of metreleptin. The authors of that study speculated that, based on observations of pediatric patients with congenital leptin deficiency, leptin may have a more significant role in the growing skeleton than in the mature skeleton (37) . The current study does not support this hypothesis because no differences in BMC were seen between children and adults either in a state of leptin deficiency or in response to metreleptin.
In rodent models of leptin deficiency, leptin administration and gene therapy have each been shown to decrease axial trabecular bone and to increase appendicular cortical bone, as assessed by histomorphometric analysis (13, 14) of bone specimens. Because of the invasiveness of this procedure, our patients did not undergo bone biopsy. Our study was also limited by the availability of only whole-body DXA in most patients, which limited the ability to distinguish changes in cortical vs trabecular bone. We attempted to address this by examining the relative contributions to total BMC of the limbs vs the axial skeleton, with the assumption that the limbs are primarily composed of cortical bone with the bulk of trabecular bone confined to the axial skeleton. Although this ratio imperfectly corrects for the effects of growth, we did not observe any change in BMC of the appendicular skeleton relative to that of the axial skeleton with metreleptin. Sitespecific data from the hip and radius were available for eight patients, and only four had both baseline and follow-up data available, limiting our statistical power to detect differences from population normative data as well as changes with metreleptin. Despite this limitation, we found that, consistent with rodent models, baseline BMD was elevated in trabecular-rich sites (spine and hip) but was not elevated in cortical-rich sites (distal radius). In our patients, there was no change in BMD SDS for any site with metreleptin, arguing against a specific role of leptin deficiency in the baseline phenotype. However, these findings require confirmation with larger numbers of patients.
Leptin has been proposed to play a role in bone and mineral homeostasis by stimulating synthesis of FGF23. In ob/ob mice, massive pharmacological doses of leptin (8 mg/kg/d; approximately 100 times the per-kilogram dose given to CGL patients) increased FGF23, thereby lowering 1,25-dihydroxyvitamin D (12) . In the leptin-deficient state, ob/ob mice have elevated 1,25-dihydroxyvitamin D, which may be a cause of the observed decreased cortical bone mass by increasing receptor activator of nuclear factor -B ligand, which stimulates bone reabsorption by enhancing osteoclast formation (38) . However, the effects of leptin replacement on receptor activator of nuclear factor -B ligand have not been directly demonstrated. Supporting these rodent data, humans with higher leptin (from obesity) have higher PTH, FGF23, and 1,25-dihydroxyvitamin D in cross-sectional studies (39) .
We were unable to measure FGF23 in the current study because appropriate samples were not available for analysis. Serum calcium in our patients significantly decreased during metreleptin replacement, which is consistent with rodent data (12) and lends support to this line of reasoning. However, no changes were seen in phosphorus, PTH, or 1,25-dihydroxyvitamin D, which is not consistent with the mechanism proposed to explain the rodent data. Moreover, although the decrease in calcium was statistically significant, serum calcium levels remained within normal limits. This finding is therefore of unclear significance, and further investigation is needed to clarify the role of leptin in FGF23 pathways in humans.
In summary, unlike rodents, humans with CGL have high BMC in the leptin-deficient state, and BMC does not change with metreleptin treatment. Although our study had small numbers of patients, a post hoc power analysis showed Ͼ 80% power to detect changes in TBLH BMC of 1 SDS; this change has been shown to be associated with a change in fracture risk (36) and is thus clinically significant. The observed change in TBLH BMC SDS with metreleptin was less than 0.5 at almost all time points; even with larger numbers to increase power, this change is unlikely to be clinically significant. Although the study was further limited by the use of whole-body DXA in most patients, as well as a genetically and developmentally heterogeneous patient population, these data call into question the translatability to humans of important rodent findings on the role of leptin in bone and mineral metabolism. Our findings require confirmation in additional, larger, prospective studies of leptin replacement in CGL and other leptin-deficient states, including accurate assessment of cortical and trabecular bone, as well as FGF23 metabolism.
